Sanofi to acquire Vigil Neuroscience for $600m.

Sanofi, a company specializing in pharmaceuticals and vaccines, agreed to acquire Vigil Neuroscience, a biotechnology company, for $600m. "We are incredibly proud of the legacy we have built at Vigil and today’s announcement is a testament to the value of our TREM2 agonist pipeline. Sanofi’s development capabilities, therapeutic expertise, global footprint, and financial strength provide the greatest opportunity to further the development of VG-3927 for the potential treatment of Alzheimer’s disease and potentially bring this important and differentiated therapy to those struggling with the immense burden of this disease,” Ivana Magovčević-Liebisch, Vigil President and Chief Executive Officer.